PRISM Research Studies
Current Interventional Research Studies
EXTINGUISH BioDirects ExoFlo
Phase III study evaluating an intravenous administration of an intervention (bone marrow mesenchymal stem cell derived extracellular vesicles) compared to a placebo on the treatment of hospitalized patients with moderate to severe ARDS.
CHILL
Phase IIb study comparing therapeutic hypothermia (core temperature 34 - 35 degrees Celsius) and neuromuscular blocking agents versus usual temperature management. This study aims to evaluate whether therapeutic hypothermia and neuromuscular blocking agents combined are beneficial in patients with ARDS.
SLICC
Study that collects biospecimens via bronchoscopy in ARDS patients to evaluate early onset markers, ventilator-free days, oxygenation change, 28-day mortality, and secondary infections to guide improved patient care and treatment strategies.
PREVENT-VILI
Phase III study that aims to assess mechanical ventilation strategies—including driving pressure and esophageal manometry—to optimize ventilation in patients with moderate to severe ARDS.
OPTIMIZE
Phase IV study that aims to assess the role of Cystatin C (CysC) and CysC-based eGFR equations in characterizing pharmacokinetic (PK) profiles of meropenem and cefepime in critically ill adults with suspected or confirmed antimicrobial-resistant Gram-negative infections.
ANGLE
Objective: To compare the use of a hyperangulated video laryngoscope blade versus a standard geometry video laryngoscope blade during emergency intubation.
WAVE
Objective: Compare waveform capnography vs. colorimetric CO₂ detectors for confirming endotracheal tube placement in critically ill adults. This study aims to identify the more accurate method, especially in patients with low cardiac output or airflow obstruction. Patients receive both devices during intubation.
PRACTICAL
Objective: The primary objective of this platform trial is to identify the invasive mechanical ventilation strategy that most effectively improves patient outcomes among a range of strategies including conventional lung-protection ventilation.
VBI-S
Phase II study that aims to evaluate the safety and efficacy of VBI-S, a phospholipid nanoparticle-based fluid, in elevating blood pressure in septic shock patients experiencing absolute or relative hypovolemia.
Completed Research Studies
SAVE-O2
Study that aims to evaluate the effectiveness of the O₂matic PRO100—a closed-loop, autonomous oxygen titration system—in maintaining normoxemia (oxygen saturation of 90–96%) in non-mechanically ventilated patients in acute care. This study aims to confirm the system’s reliability, efficiency, and practicality in real-world settings.
JAZZ
Study quantifying blood pressure change when patients with narcolepsy are treated with high sodium oxybate then transitioned to XYWAV, a low sodium oxybate. The goal of this study is to improve provider care by providing new information on changes in blood pressure related to narcolepsy treatment.
STRIVE
Immune modulation trial comparing early intensification of immune modulation (patients on low flow oxygen) with the study treatment abatacept and standard of care, versus a placebo and standard of care, on outcomes of patients hospitalized with COVID-19.
IVY 6
Public health observational study evaluating the efficacy of both COVID-19 vaccines on the prevention of COVID-19 hospitalizations, and influenza vaccines on the prevention of influenza hospitalizations.
LIBERATION
Observational study evaluating the implementation of evidence-based ICU care and the associated effect on the outcomes of patients with ARDS who have been admitted to the ICU and mechanically ventilated.
IHCA
Observational study that aims to better understand variation across in-hospital cardiac arrest and post-resuscitation care. This study focuses specifically on temperature control and neuroprognostication approaches.
DOMPE PNA (REPO321)
Phase III study on the efficacy and safety of reparixin compared to standard care on limiting disease progression in adult patients hospitalized with community acquired pneumonia (including COVID-19). Efficacy will be measured by recovery, ventilator free days, and mortality.
DOMPE ARDS (REPO122)
Phase II study on the efficacy and safety of reparixin in adult patients hospitalized with moderate to severe ARDS, with the goal of improving lung injury and inflammation and decreasing time spent on mechanical ventilation. Each participant will receive ARDS standard care and be assigned to either reparixin or a placebo.
COMBO 1
Phase II-like trial comparing a combination treatment of oseltamivir and baloxavir, versus a standard treatment of oseltamivir and a placebo, on outcomes of patients with influenza.
BOA
Study evaluating the efficacy and safety of combined hemodialysis with the GARNET™ device. Participants consist of chronic hemodialysis patients who have a blood stream infection and will receive two sessions of hemodialysis with the GARNET™ device.
PREOXI
Study comparing the efficacy of two standard care preoxygenation methods: non-invasive positive pressure ventilation and facemask oxygen. This study aims to better understand the effectiveness of these two methods in order to improve provider care and patient outcomes.
ROCHE
Study investigating the plasma pharmacokinetics and safety of intravenous administration of a single dose (400mg or 600mg) of the study treatment RO7223280 in critically ill patients with bacterial infections.
ACTIV 1
ACTIV 1
Study evaluating different study treatments on moderately to severely ill patients with COVID-19. Participants consist of patients hospitalized or being treated for COVID-19 infection and will receive standard care and a study treatment. Treatments are evaluated on speed of recovery, mortality, illness severity, and hospital resource use.
ACTIV 2
Study evaluating the efficacy and safety of different study treatments on outpatients with COVID-19. Study treatments include infused and non-infused agents, and based on the adaptive trial design, can be tested in phase II and phase III of the same trial infrastructure.
ACTIV 3b
Study evaluating the efficacy of different drugs for treating COVID-19 in patients who have been hospitalized with COVID-19 and have acute respiratory failure. Participants are treated with a study drug and standard care, or a placebo and standard care.
ACTIV 4a
Study evaluating study treatments added to existing standard care therapies on adult patients hospitalized with COVID-19. Study treatments will consist of antithrombotic therapies that have been shown to be effective when combined with other treatments to treat COVID-19 patients.
ACTIV 4c
Study evaluating efficacy and safety of antithrombotic compared to no antithrombotic therapy on patients hospitalized with COVID-19. Participants will receive either prophylactic anticoagulation or a placebo, with the goal of preventing further illness and all-cause mortality.
ACTIV 4d (NECTAR)
Study evaluating whether host tissue response modulation improves clinical outcomes of patients hospitalized with COVID-19. This study is part of the Master Host Tissue Protocol, which consists of trials measuring the efficacy of study treatments targeting the host response in COVID-19.